Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IBRX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel… NCT06745908 · NSCLC Stage IV N-803, Tislelizumab | IBRX ImmunityBio, Inc. | Phase 3 | Recruiting | 507 | Sep 2028 | Registry ↗ |
| Nov 2, 2026 | QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors NCT04898543 · Metastatic Solid Tumor M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Co… | IBRX ImmunityBio, Inc. | Phase 1 | Active, not recruiting | 50 | Feb 2, 2026 | Registry ↗ |
| Nov 2, 2026 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy f… NCT04390399 · Pancreatic Cancer N-803, Aldoxorubicin HCl | IBRX ImmunityBio, Inc. | Phase 2 | Active, not recruiting | 328 | Oct 13, 2025 | Registry ↗ |
| Sep 25, 2026 | NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With… NCT07783789 · Sepsis Nogapendekin alfa inbakicept (NAI), Placebo | IBRX ImmunityBio, Inc. | Phase 2 | Not yet recruiting | 50 | May 12, 2028 | Registry ↗ |
| Sep 24, 2026 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV) | IBRX ImmunityBio, Inc. | Phase 1 | Not yet recruiting | 18 | Jan 2028 | Registry ↗ |
| Sep 24, 2026 | A Study to Examine Anktiva for the Treatment of COVID-19. NCT07123727 · Long COVID, Long COVID Syndrome Anktiva | IBRX ImmunityBio, Inc. | Phase 2 | Recruiting | 40 | Mar 2027 | Registry ↗ |
| Aug 31, 2026 | IBRX-042 In Participants With HPV-Associated Tumors NCT05976828 · HPV-Related Carcinoma IBRX-042 | IBRX ImmunityBio, Inc. | Phase 1 | Active, not recruiting | 12 | Sep 2, 2027 | Registry ↗ |
| Aug 28, 2026 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zab… NCT07488884 · Pancreatic Cancer Resectable, Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab | IBRX ImmunityBio, Inc. | Phase 1 | Withdrawn | 0 | Jun 1, 2027 | Registry ↗ |
| Aug 19, 2026 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia NCT07556757 · B-ALL, Leukemia CD19 t-haNK | IBRX ImmunityBio, Inc. | Phase 1 | Terminated | 4 | Jul 1, 2026 | Registry ↗ |
| Jul 10, 2026 | Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma NCT06334991 · Non-Hodgkin Lymphoma Refractory/ Relapsed CD19 t-haNK | IBRX ImmunityBio, Inc. | Phase 1 | Active, not recruiting | 20 | Oct 2027 | Registry ↗ |
| Jul 1, 2026 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15… NCT06710288 · Platinum-resistant Ovarian Cancer Gemcitabine, N-803 | IBRX ImmunityBio, Inc. | Phase 2 | Recruiting | 20 | May 2027 | Registry ↗ |
| Jul 1, 2026 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma NCT06061809 · Glioblastoma Bevacizumab, PD-L1 t-haNK | IBRX ImmunityBio, Inc. | Phase 2 | Active, not recruiting | 34 | Dec 31, 2029 | Registry ↗ |
| Jun 22, 2026 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Li… NCT07524257 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSC… Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab | IBRX ImmunityBio, Inc. | Phase 3 | Withdrawn | 0 | May 15, 2029 | Registry ↗ |
| Jun 4, 2026 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed… NCT07628062 · HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Orophar… Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-… | IBRX ImmunityBio, Inc. | Phase 2 | Not yet recruiting | 70 | Dec 31, 2030 | Registry ↗ |
| May 26, 2026 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer NCT03520686 · Non Small Cell Lung Cancer NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab | IBRX ImmunityBio, Inc. | Phase 3 | Terminated | 102 | Oct 13, 2025 | Registry ↗ |
| May 19, 2026 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-M… NCT07551544 · NMIBC BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) | IBRX ImmunityBio, Inc. | Phase 3 | Withdrawn | 0 | May 2032 | Registry ↗ |
| May 14, 2026 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive… NCT06810141 · NMIBC rMBCG | IBRX ImmunityBio, Inc. | — | Available | — | — | Registry ↗ |
| May 11, 2026 | NAI for Sepsis With Persistent Lymphopenia NCT07578558 · Sepsis, Septic Shock Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) | IBRX ImmunityBio, Inc. | Phase 2 | Not yet recruiting | 50 | Aug 3, 2027 | Registry ↗ |
| May 11, 2026 | A Study to Assess Anktiva in Patients With Long Covid-19. NCT07108036 · Long COVID N-803 (IL-15 Superagonist) | IBRX ImmunityBio, Inc. | Phase 2 | Recruiting | 20 | Oct 2026 | Registry ↗ |
| May 8, 2026 | Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquire… NCT07492888 · Acute Respiratory Distress Syndrome, Severe Community-Acqui… Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Na… | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Nov 15, 2026 | Registry ↗ |
| May 8, 2026 | Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community… NCT07492875 · Community-Acquired Pneumonia (CAP), Acute Respiratory Distr… Nogapendekin alfa inbakicept (NAI), agenT-797 | IBRX ImmunityBio, Inc. | Phase 3 | Withdrawn | 0 | Apr 15, 2029 | Registry ↗ |
| May 5, 2026 | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With… NCT06765954 · High-risk Prostate Cancer N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic V… | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Jan 31, 2031 | Registry ↗ |
| May 5, 2026 | Immunotherapy Before and After Surgery NCT06765902 · High-risk Prostate Cancer N-803, ETBX-071 | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Jan 31, 2031 | Registry ↗ |
| May 4, 2026 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma NCT07125872 · Relapsed B-Cell Non Hodgkin Lymphoma CD19 t-haNK- IV Administration | IBRX ImmunityBio, Inc. | Phase 2 | Recruiting | 20 | May 25, 2027 | Registry ↗ |
| Apr 29, 2026 | Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) NCT05981131 · Non Muscle Invasive Bladder Cancer N803 plus Bacillus Calmette-Guerin (BCG) | IBRX ImmunityBio, Inc. | — | Active, not recruiting | 6 | Aug 30, 2033 | Registry ↗ |
| Apr 15, 2026 | HCW9218 for Advanced Pancreatic Cancer NCT05304936 · Advanced Pancreatic Carcinoma HCW9218, Gemcitabine (GEM) | IBRX ImmunityBio, Inc. | Phase 1/2 | Completed | 21 | Feb 15, 2025 | Registry ↗ |
| Apr 1, 2026 | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma NCT05618925 · Non Hodgkin's Lymphoma Refractory/Relapsed N803, CD19t-haNK suspension | IBRX ImmunityBio, Inc. | Phase 1 | Recruiting | 20 | May 15, 2026 | Registry ↗ |
| Apr 1, 2026 | QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers NCT04050709 · Locally Advanced Solid Tumor, Metastatic Cancer PD-L1 t-haNK | IBRX ImmunityBio, Inc. | Phase 1 | Completed | 16 | Mar 30, 2021 | Registry ↗ |
| Mar 31, 2026 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladde… NCT02138734 · Non-muscle Invasive Bladder Cancer BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG… | IBRX ImmunityBio, Inc. | Phase 1/2 | Active, not recruiting | 369 | Sep 30, 2026 | Registry ↗ |
| Mar 27, 2026 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible… NCT06800963 · NMIBC Intravesical Recombinant Mycobacterium (rMBCG) | IBRX ImmunityBio, Inc. | Phase 1/2 | Recruiting | 40 | Feb 2028 | Registry ↗ |
| Mar 17, 2026 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma NCT07477366 · Relapsed B-Cell Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803 | IBRX ImmunityBio, Inc. | Phase 2 | Not yet recruiting | 20 | Dec 2027 | Registry ↗ |
| Jan 14, 2026 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatm… NCT03228667 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer N-803 + Pembrolizumab, N-803 + Nivolumab | IBRX ImmunityBio, Inc. | Phase 2 | Active, not recruiting | 40 | Aug 31, 2029 | Registry ↗ |
| Oct 16, 2025 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papil… NCT06829823 · Non-muscle Invasive Bladder Cancer (NMIBC) N-803 and BCG, N-803 and Gemcitabine | IBRX ImmunityBio, Inc. | Phase 2 | Not yet recruiting | 20 | Nov 2026 | Registry ↗ |
| Oct 16, 2025 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combina… NCT03022825 · Bladder Cancer N-803 and BCG, N-803 | IBRX ImmunityBio, Inc. | Phase 2/3 | Active, not recruiting | 190 | Oct 1, 2024 | Registry ↗ |
| Oct 14, 2025 | Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lym… NCT06956547 · Lymphopenia nogapendekin-alfa inbakicept | IBRX ImmunityBio, Inc. | — | Available | — | — | Registry ↗ |
| Oct 14, 2025 | Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer… NCT06040918 · Healthy Subjects N-803 | IBRX ImmunityBio, Inc. | Phase 1 | Completed | 10 | Sep 3, 2024 | Registry ↗ |
| Mar 11, 2025 | THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines NCT05370040 · COVID-19 AAHI-SC2 Vaccine, AAHI-SC3 Vaccine | IBRX ImmunityBio, Inc. | Phase 1/2 | Terminated | 60 | Mar 11, 2024 | Registry ↗ |
| Feb 24, 2025 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Re… NCT03169790 · Non Hodgkin Lymphoma avelumab, bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2019 | Registry ↗ |
| Feb 24, 2025 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy… NCT03169764 · Head and Neck Squamous Cell Carcinoma Avelumab, Bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2019 | Registry ↗ |
| Feb 21, 2025 | COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protec… NCT04845191 · Covid19 hAd5-S-Fusion+N-ETSD vaccine | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Dec 2021 | Registry ↗ |
| Feb 21, 2025 | COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received… NCT04843722 · Covid19 hAd5-S-Fusion+N-ETSD vaccine | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Dec 2021 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma NCT04052061 · Diffuse Large B Cell Lymphoma, Large-cell Lymphoma CD19 t-haNK | IBRX ImmunityBio, Inc. | Phase 1 | Withdrawn | 0 | Sep 18, 2021 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. NCT03647423 · Chordoma, Unresectable Malignant Neoplasm Aldoxorubicin Hydrochloride, ALT-803 | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Aug 31, 2020 | Registry ↗ |
| Feb 21, 2025 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus… NCT03574649 · Non Small Cell Lung Cancer Nab-paclitaxel, Cisplatin | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Aug 2018 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.088: NANT Pancreatic Cancer Vaccine NCT03563144 · Metastatic Pancreatic Cancer Gemcitabine, Nab-paclitaxel | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Dec 30, 2019 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine NCT03554109 · Triple Negative Breast Cancer (TNBC) Leucovorin, 5-Fluorouracil | IBRX ImmunityBio, Inc. | Phase 2 | Withdrawn | 0 | Jun 2020 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ova… NCT03197584 · Ovarian Cancer Avelumab, Bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Feb 2019 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial… NCT03197571 · Urothelial Carcinoma avelumab, bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2019 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjec… NCT03175666 · Triple Negative Breast Cancer avelumab, bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2019 | Registry ↗ |
| Feb 21, 2025 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recur… NCT03169777 · Colorectal Cancer avelumab, bevacizumab | IBRX ImmunityBio, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2019 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:45 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances